Cargando…
A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
Increased leucine‐rich repeat kinase 2 (LRRK2) kinase activity is an established risk factor for Parkinson's disease (PD), and several LRRK2 kinase inhibitors are in clinical development as potential novel disease‐modifying therapeutics. This biomarker characterization study explored within‐ an...
Autores principales: | Vissers, Maurits F. J. M., Troyer, Matthew D., Thijssen, Eva, Pereira, Diana R., Heuberger, | Jules A. A. C., Groeneveld, Geert Jan, Huntwork‐Rodriguez, Sarah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432885/ https://www.ncbi.nlm.nih.gov/pubmed/37177855 http://dx.doi.org/10.1111/cts.13541 |
Ejemplares similares
-
Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010) -
Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2):
Parkinson’s disease and beyond
por: Bae, Jae Ryul, et al.
Publicado: (2015) -
Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia
por: Maekawa, Tatsunori, et al.
Publicado: (2016) -
The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)
por: Konstantinidou, Markella, et al.
Publicado: (2020) -
Generation of fourteen isogenic cell lines for Parkinson’s disease-associated leucine-rich repeat kinase (LRRK2)
por: Beylina, Aleksandra, et al.
Publicado: (2021)